“Five states representing 60% of the total assets in the country are: Maharashtra (29. 5%), Karnataka (9. 9%), Andhra Pradesh (9. 4%), Uttar Pradesh (6. 8%) and Tamil Nadu (4. 7%), said Rajesh Bhushan, secretary of the Ministry of Health and Family Welfare.
The government has observed an upward trend in instances in Maharashtra, while stabilization has been observed over the more than 3 weeks in Karnataka. Uttar Pradesh is showing an upward trend, while stabilization over the next 3 weeks is also observed in Andhra Pradesh and Tamil Nadu is appearing early symptoms of declining cases,” Bhushan said.
The number of covid-19 deaths in India reached 81,331 on Tuesday. The union’s Ministry of Health also analyzed the trend of average deaths weekly in the top five states. Research shows an upward trend in Maharashtra, while showing some stabilization. karnataka. ” There is also an upward trend in deaths in Uttar Pradesh, while Andhra Pradesh is seeing early symptoms of decline over more than 3 weeks and Tamil Nadu is appearing symptoms of decline over more than 4 weeks,” Bhushan said.
When studying the number of tests in conjunction with the positivity rates of the respective states, we find that Maharashtra has a positivity rate of 21. 5% and therefore requires higher testing. aim to keep their positivity rates below the national average (8. 4%), the Ministry of Health said.
This week, more than 38. 59 lakh of patients recovered from covid-19 in India, one of the world’s, according to Johns Hopkins University’s Coronavirus Resource Center, this is the largest number of recoveries in the world.
Ensuring that there is no shortage of oxygen to treat critical covid-19 patients, the government stated that about 6% of covid-19 patients nationwide needed oxygen support. Bhushan claimed that India has a production capacity of 6,900 metric tons of consistent oxygen per day about 2,800 metric tons of oxygen is needed for covid-19 and non-covid health use, and some 2,200 metric tons are used for commercial purposes, so domestics there is no shortage of oxygen and today in the morning surplus of 1,900 metric tons of oxygen Bhushan said.
India is actively involved in the progression of a vaccine opposed to covid-19. “Phase 2 trials from Cadila and Bharat Biotech are underway, while the Serum Institute is about to begin phase 3 trials at 15 sites across the country,” Dr. Balram said. Bhargava, Executive Director, Medical Research Council of India (ICMR)
Referring to the vaccine developed in Russia, the head of the ICMR said that dialogues are taking place between the High-Level Committee on Vaccines and Russian diplomats on the mechanisms for conducting a Phase 3 trial in India.
India is also reading the effectiveness of plasma therapy. “Randomized controlled trials in 464 patients in 39 hospitals in 25 districts in 14 states/UT have shown that it does not reduce mortality or prevent moderate to severe disease progression. the effects are being peer-reviewed,” Bhargava said.
The national organization of brokers and the joint monitoring organization of the Ministry of Health and Family Welfare will take a resolution on the continuity of plasma treatment once the full publication is published after the peer review of the results, he said, adding that there are times where reactions would possibly occur and that is why we will take a considered opinion once we have the full publication of this study.
The ICMR also indicated that the national serological survey, conducted in April-May and repeated after 3 months, ended in 68 of the 70 districts. “After analyzing the effects until the end of the month, the two studies can be compared. The serological survey also highlights the infection mortality rate, which was found between 0. 5 and 0. 6 in the latest national serological survey, which is much lower than in many other countries,” he said.
Click here to read that Mint ePapermint is now on Telegram. Join the mint channel in your telegram and updated
Log in to our to save your favorites. It’ll only take a moment.
Your query has expired, reconnect.
You are now subscribed to our newsletters. If you can’t find any of our emails, check your spam folder.